nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—SLC7A5—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.00625	0.219	CbGdCrCtD
L-DOPA—SLC7A5—Tretinoin—Acitretin—psoriasis	0.00475	0.166	CbGdCrCtD
L-DOPA—SLC7A5—Alitretinoin—Acitretin—psoriasis	0.00475	0.166	CbGdCrCtD
L-DOPA—SLC7A5—Isotretinoin—Acitretin—psoriasis	0.00475	0.166	CbGdCrCtD
L-DOPA—Mesalazine—PPARG—psoriasis	0.00259	0.662	CrCbGaD
L-DOPA—SLC7A5—Hemostasis—SERPINB8—psoriasis	0.0016	0.0235	CbGpPWpGaD
L-DOPA—SLC7A5—Desoximetasone—Clobetasol propionate—psoriasis	0.00135	0.0472	CbGdCrCtD
L-DOPA—Epinephrine—TNF—psoriasis	0.00132	0.339	CrCbGaD
L-DOPA—DDC—Tryptophan metabolism—CAT—psoriasis	0.00128	0.0189	CbGpPWpGaD
L-DOPA—PSIP1—Host Interactions of HIV factors—HLA-A—psoriasis	0.00117	0.0172	CbGpPWpGaD
L-DOPA—SLC7A5—Desoximetasone—Beclomethasone—psoriasis	0.00108	0.0378	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Fluocinonide—psoriasis	0.00108	0.0378	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Fluocinolone Acetonide—psoriasis	0.00105	0.0367	CbGdCrCtD
L-DOPA—SLC7A5—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000996	0.0146	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000923	0.0136	CbGpPWpGaD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—CP—psoriasis	0.000876	0.0129	CbGpPWpGaD
L-DOPA—SLC7A5—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000861	0.0127	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.0008	0.0118	CbGpPWpGaD
L-DOPA—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000794	0.0117	CbGpPWpGaD
L-DOPA—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000783	0.0115	CbGpPWpGaD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—CP—psoriasis	0.000765	0.0112	CbGpPWpGaD
L-DOPA—PSIP1—HIV Infection—HLA-A—psoriasis	0.000761	0.0112	CbGpPWpGaD
L-DOPA—PSIP1—Host Interactions of HIV factors—CD4—psoriasis	0.000755	0.0111	CbGpPWpGaD
L-DOPA—DDC—Dopaminergic Neurogenesis—STAT3—psoriasis	0.00075	0.011	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—HCAR2—psoriasis	0.000743	0.0109	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—IL13—psoriasis	0.000729	0.0107	CbGpPWpGaD
L-DOPA—PSIP1—HIV Life Cycle—CD4—psoriasis	0.00071	0.0104	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—HCAR2—psoriasis	0.00066	0.0097	CbGpPWpGaD
L-DOPA—SLC7A5—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.000645	0.00947	CbGpPWpGaD
L-DOPA—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000644	0.00946	CbGpPWpGaD
L-DOPA—PSIP1—Levonorgestrel—Hydrocortisone—psoriasis	0.000612	0.0214	CbGdCrCtD
L-DOPA—DRD5—GPCR ligand binding—HCAR2—psoriasis	0.000609	0.00896	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000591	0.00868	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—ITGAL—psoriasis	0.000533	0.00783	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000532	0.00781	CbGpPWpGaD
L-DOPA—SLC7A5—Desoximetasone—Hydrocortisone—psoriasis	0.00053	0.0185	CbGdCrCtD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000525	0.00771	CbGpPWpGaD
L-DOPA—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000518	0.000575	CcSEcCtD
L-DOPA—Pain—Cyclosporine—psoriasis	0.000515	0.000573	CcSEcCtD
L-DOPA—Constipation—Cyclosporine—psoriasis	0.000515	0.000573	CcSEcCtD
L-DOPA—Dry mouth—Triamcinolone—psoriasis	0.000515	0.000572	CcSEcCtD
L-DOPA—Angioedema—Betamethasone—psoriasis	0.000512	0.00057	CcSEcCtD
L-DOPA—Angioedema—Dexamethasone—psoriasis	0.000512	0.00057	CcSEcCtD
L-DOPA—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000511	0.000568	CcSEcCtD
L-DOPA—Anorexia—Hydrocortisone—psoriasis	0.000511	0.000568	CcSEcCtD
L-DOPA—Diarrhoea—Mycophenolic acid—psoriasis	0.00051	0.000567	CcSEcCtD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—CP—psoriasis	0.000508	0.00747	CbGpPWpGaD
L-DOPA—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000508	0.000564	CcSEcCtD
L-DOPA—Malaise—Betamethasone—psoriasis	0.000506	0.000562	CcSEcCtD
L-DOPA—Malaise—Dexamethasone—psoriasis	0.000506	0.000562	CcSEcCtD
L-DOPA—DRD2—G alpha (i) signalling events—HCAR2—psoriasis	0.000505	0.00742	CbGpPWpGaD
L-DOPA—Oedema—Triamcinolone—psoriasis	0.000504	0.000561	CcSEcCtD
L-DOPA—Syncope—Betamethasone—psoriasis	0.000503	0.000559	CcSEcCtD
L-DOPA—Syncope—Dexamethasone—psoriasis	0.000503	0.000559	CcSEcCtD
L-DOPA—Constipation—Mycophenolate mofetil—psoriasis	0.000503	0.000559	CcSEcCtD
L-DOPA—Pain—Mycophenolate mofetil—psoriasis	0.000503	0.000559	CcSEcCtD
L-DOPA—Arrhythmia—Prednisone—psoriasis	0.000501	0.000557	CcSEcCtD
L-DOPA—Hypotension—Hydrocortisone—psoriasis	0.000501	0.000556	CcSEcCtD
L-DOPA—Feeling abnormal—Cyclosporine—psoriasis	0.000497	0.000552	CcSEcCtD
L-DOPA—Shock—Triamcinolone—psoriasis	0.000496	0.000552	CcSEcCtD
L-DOPA—Insomnia—Prednisolone—psoriasis	0.000496	0.000552	CcSEcCtD
L-DOPA—Alopecia—Prednisone—psoriasis	0.000496	0.000551	CcSEcCtD
L-DOPA—Gastrointestinal pain—Cyclosporine—psoriasis	0.000493	0.000548	CcSEcCtD
L-DOPA—Loss of consciousness—Dexamethasone—psoriasis	0.000493	0.000548	CcSEcCtD
L-DOPA—Loss of consciousness—Betamethasone—psoriasis	0.000493	0.000548	CcSEcCtD
L-DOPA—Dizziness—Mycophenolic acid—psoriasis	0.000493	0.000548	CcSEcCtD
L-DOPA—Paraesthesia—Prednisolone—psoriasis	0.000492	0.000548	CcSEcCtD
L-DOPA—SLC7A5—Desoximetasone—Betamethasone—psoriasis	0.000492	0.0172	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Dexamethasone—psoriasis	0.000492	0.0172	CbGdCrCtD
L-DOPA—Mental disorder—Prednisone—psoriasis	0.000491	0.000546	CcSEcCtD
L-DOPA—PSIP1—HIV Infection—CD4—psoriasis	0.00049	0.00721	CbGpPWpGaD
L-DOPA—Hyperhidrosis—Triamcinolone—psoriasis	0.000488	0.000542	CcSEcCtD
L-DOPA—Agranulocytosis—Methotrexate—psoriasis	0.000487	0.000542	CcSEcCtD
L-DOPA—Convulsion—Betamethasone—psoriasis	0.000486	0.00054	CcSEcCtD
L-DOPA—Convulsion—Dexamethasone—psoriasis	0.000486	0.00054	CcSEcCtD
L-DOPA—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000485	0.000539	CcSEcCtD
L-DOPA—Insomnia—Hydrocortisone—psoriasis	0.000484	0.000539	CcSEcCtD
L-DOPA—Hypertension—Dexamethasone—psoriasis	0.000484	0.000538	CcSEcCtD
L-DOPA—Hypertension—Betamethasone—psoriasis	0.000484	0.000538	CcSEcCtD
L-DOPA—Paraesthesia—Hydrocortisone—psoriasis	0.000481	0.000535	CcSEcCtD
L-DOPA—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000481	0.000535	CcSEcCtD
L-DOPA—SLC7A5—Desoximetasone—Triamcinolone—psoriasis	0.000481	0.0168	CbGdCrCtD
L-DOPA—Urticaria—Cyclosporine—psoriasis	0.000479	0.000532	CcSEcCtD
L-DOPA—Abdominal pain—Cyclosporine—psoriasis	0.000476	0.00053	CcSEcCtD
L-DOPA—Anxiety—Dexamethasone—psoriasis	0.000476	0.000529	CcSEcCtD
L-DOPA—Anxiety—Betamethasone—psoriasis	0.000476	0.000529	CcSEcCtD
L-DOPA—Vomiting—Mycophenolic acid—psoriasis	0.000474	0.000527	CcSEcCtD
L-DOPA—Discomfort—Betamethasone—psoriasis	0.000472	0.000524	CcSEcCtD
L-DOPA—Discomfort—Dexamethasone—psoriasis	0.000472	0.000524	CcSEcCtD
L-DOPA—Dyspepsia—Hydrocortisone—psoriasis	0.000472	0.000524	CcSEcCtD
L-DOPA—Haemoglobin—Methotrexate—psoriasis	0.000471	0.000524	CcSEcCtD
L-DOPA—Rash—Mycophenolic acid—psoriasis	0.00047	0.000522	CcSEcCtD
L-DOPA—Dermatitis—Mycophenolic acid—psoriasis	0.000469	0.000522	CcSEcCtD
L-DOPA—Pain—Prednisolone—psoriasis	0.000469	0.000521	CcSEcCtD
L-DOPA—Haemorrhage—Methotrexate—psoriasis	0.000469	0.000521	CcSEcCtD
L-DOPA—Urticaria—Mycophenolate mofetil—psoriasis	0.000467	0.000519	CcSEcCtD
L-DOPA—Headache—Mycophenolic acid—psoriasis	0.000467	0.000519	CcSEcCtD
L-DOPA—Decreased appetite—Hydrocortisone—psoriasis	0.000466	0.000518	CcSEcCtD
L-DOPA—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000465	0.000517	CcSEcCtD
L-DOPA—SLC7A5—Hemostasis—ITGAL—psoriasis	0.000465	0.00683	CbGpPWpGaD
L-DOPA—Urinary tract disorder—Methotrexate—psoriasis	0.000463	0.000515	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000462	0.000514	CcSEcCtD
L-DOPA—Fatigue—Hydrocortisone—psoriasis	0.000462	0.000513	CcSEcCtD
L-DOPA—Vision blurred—Prednisone—psoriasis	0.00046	0.000512	CcSEcCtD
L-DOPA—Urethral disorder—Methotrexate—psoriasis	0.00046	0.000511	CcSEcCtD
L-DOPA—Pain—Hydrocortisone—psoriasis	0.000458	0.000509	CcSEcCtD
L-DOPA—Oedema—Dexamethasone—psoriasis	0.000458	0.000509	CcSEcCtD
L-DOPA—Oedema—Betamethasone—psoriasis	0.000458	0.000509	CcSEcCtD
L-DOPA—Insomnia—Triamcinolone—psoriasis	0.000456	0.000507	CcSEcCtD
L-DOPA—SLC7A5—Desoximetasone—Prednisone—psoriasis	0.000456	0.016	CbGdCrCtD
L-DOPA—DDC—SIDS Susceptibility Pathways—IL10—psoriasis	0.000456	0.0067	CbGpPWpGaD
L-DOPA—Ill-defined disorder—Prednisone—psoriasis	0.000453	0.000504	CcSEcCtD
L-DOPA—Paraesthesia—Triamcinolone—psoriasis	0.000453	0.000504	CcSEcCtD
L-DOPA—Feeling abnormal—Prednisolone—psoriasis	0.000452	0.000502	CcSEcCtD
L-DOPA—Anaemia—Prednisone—psoriasis	0.000451	0.000502	CcSEcCtD
L-DOPA—Shock—Betamethasone—psoriasis	0.00045	0.000501	CcSEcCtD
L-DOPA—Shock—Dexamethasone—psoriasis	0.00045	0.000501	CcSEcCtD
L-DOPA—DRD4—GPCR ligand binding—HCAR2—psoriasis	0.00045	0.00661	CbGpPWpGaD
L-DOPA—Dyspnoea—Triamcinolone—psoriasis	0.00045	0.0005	CcSEcCtD
L-DOPA—Agitation—Prednisone—psoriasis	0.000449	0.000499	CcSEcCtD
L-DOPA—Thrombocytopenia—Dexamethasone—psoriasis	0.000448	0.000498	CcSEcCtD
L-DOPA—Thrombocytopenia—Betamethasone—psoriasis	0.000448	0.000498	CcSEcCtD
L-DOPA—Angioedema—Prednisone—psoriasis	0.000446	0.000496	CcSEcCtD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—CP—psoriasis	0.000445	0.00654	CbGpPWpGaD
L-DOPA—SLC7A5—Desoximetasone—Prednisolone—psoriasis	0.000445	0.0156	CbGdCrCtD
L-DOPA—Hypersensitivity—Cyclosporine—psoriasis	0.000444	0.000494	CcSEcCtD
L-DOPA—Dyspepsia—Triamcinolone—psoriasis	0.000444	0.000494	CcSEcCtD
L-DOPA—Nausea—Mycophenolic acid—psoriasis	0.000443	0.000492	CcSEcCtD
L-DOPA—Hyperhidrosis—Betamethasone—psoriasis	0.000442	0.000492	CcSEcCtD
L-DOPA—Hyperhidrosis—Dexamethasone—psoriasis	0.000442	0.000492	CcSEcCtD
L-DOPA—Feeling abnormal—Hydrocortisone—psoriasis	0.000441	0.000491	CcSEcCtD
L-DOPA—Malaise—Prednisone—psoriasis	0.00044	0.00049	CcSEcCtD
L-DOPA—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000438	0.000487	CcSEcCtD
L-DOPA—Syncope—Prednisone—psoriasis	0.000438	0.000487	CcSEcCtD
L-DOPA—Anorexia—Dexamethasone—psoriasis	0.000436	0.000485	CcSEcCtD
L-DOPA—Anorexia—Betamethasone—psoriasis	0.000436	0.000485	CcSEcCtD
L-DOPA—Urticaria—Prednisolone—psoriasis	0.000436	0.000484	CcSEcCtD
L-DOPA—Fatigue—Triamcinolone—psoriasis	0.000435	0.000483	CcSEcCtD
L-DOPA—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000433	0.000482	CcSEcCtD
L-DOPA—Asthenia—Cyclosporine—psoriasis	0.000432	0.000481	CcSEcCtD
L-DOPA—Pain—Triamcinolone—psoriasis	0.000431	0.00048	CcSEcCtD
L-DOPA—Loss of consciousness—Prednisone—psoriasis	0.000429	0.000477	CcSEcCtD
L-DOPA—Hypotension—Betamethasone—psoriasis	0.000428	0.000475	CcSEcCtD
L-DOPA—Hypotension—Dexamethasone—psoriasis	0.000428	0.000475	CcSEcCtD
L-DOPA—Pruritus—Cyclosporine—psoriasis	0.000426	0.000474	CcSEcCtD
L-DOPA—Urticaria—Hydrocortisone—psoriasis	0.000426	0.000473	CcSEcCtD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—CARM1—psoriasis	0.000425	0.00624	CbGpPWpGaD
L-DOPA—Abdominal pain—Hydrocortisone—psoriasis	0.000423	0.000471	CcSEcCtD
L-DOPA—Convulsion—Prednisone—psoriasis	0.000423	0.00047	CcSEcCtD
L-DOPA—Asthenia—Mycophenolate mofetil—psoriasis	0.000422	0.000469	CcSEcCtD
L-DOPA—Hypertension—Prednisone—psoriasis	0.000422	0.000469	CcSEcCtD
L-DOPA—Pruritus—Mycophenolate mofetil—psoriasis	0.000416	0.000462	CcSEcCtD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000416	0.00611	CbGpPWpGaD
L-DOPA—Feeling abnormal—Triamcinolone—psoriasis	0.000416	0.000462	CcSEcCtD
L-DOPA—Anxiety—Prednisone—psoriasis	0.000414	0.000461	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—psoriasis	0.000414	0.000461	CcSEcCtD
L-DOPA—Insomnia—Betamethasone—psoriasis	0.000414	0.00046	CcSEcCtD
L-DOPA—Insomnia—Dexamethasone—psoriasis	0.000414	0.00046	CcSEcCtD
L-DOPA—Diarrhoea—Cyclosporine—psoriasis	0.000412	0.000458	CcSEcCtD
L-DOPA—Paraesthesia—Betamethasone—psoriasis	0.000411	0.000457	CcSEcCtD
L-DOPA—Paraesthesia—Dexamethasone—psoriasis	0.000411	0.000457	CcSEcCtD
L-DOPA—Discomfort—Prednisone—psoriasis	0.000411	0.000457	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—psoriasis	0.000411	0.000457	CcSEcCtD
L-DOPA—DRD1—GPCR ligand binding—HCAR2—psoriasis	0.000405	0.00595	CbGpPWpGaD
L-DOPA—Hypersensitivity—Prednisolone—psoriasis	0.000404	0.000449	CcSEcCtD
L-DOPA—Dyspepsia—Dexamethasone—psoriasis	0.000403	0.000448	CcSEcCtD
L-DOPA—Dyspepsia—Betamethasone—psoriasis	0.000403	0.000448	CcSEcCtD
L-DOPA—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000402	0.000447	CcSEcCtD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000401	0.0059	CbGpPWpGaD
L-DOPA—Urticaria—Triamcinolone—psoriasis	0.000401	0.000445	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—psoriasis	0.0004	0.000444	CcSEcCtD
L-DOPA—DRD3—GPCR ligand binding—HCAR2—psoriasis	0.000399	0.00587	CbGpPWpGaD
L-DOPA—Dizziness—Cyclosporine—psoriasis	0.000399	0.000443	CcSEcCtD
L-DOPA—Oedema—Prednisone—psoriasis	0.000399	0.000443	CcSEcCtD
L-DOPA—Decreased appetite—Dexamethasone—psoriasis	0.000398	0.000442	CcSEcCtD
L-DOPA—Decreased appetite—Betamethasone—psoriasis	0.000398	0.000442	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Betamethasone—psoriasis	0.000395	0.000439	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000395	0.000439	CcSEcCtD
L-DOPA—Back pain—Methotrexate—psoriasis	0.000395	0.000439	CcSEcCtD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—CP—psoriasis	0.000395	0.0058	CbGpPWpGaD
L-DOPA—Hypersensitivity—Hydrocortisone—psoriasis	0.000395	0.000439	CcSEcCtD
L-DOPA—Fatigue—Betamethasone—psoriasis	0.000395	0.000439	CcSEcCtD
L-DOPA—Fatigue—Dexamethasone—psoriasis	0.000395	0.000439	CcSEcCtD
L-DOPA—Shock—Prednisone—psoriasis	0.000392	0.000436	CcSEcCtD
L-DOPA—Pain—Dexamethasone—psoriasis	0.000391	0.000435	CcSEcCtD
L-DOPA—Pain—Betamethasone—psoriasis	0.000391	0.000435	CcSEcCtD
L-DOPA—Dizziness—Mycophenolate mofetil—psoriasis	0.000389	0.000432	CcSEcCtD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—CP—psoriasis	0.000389	0.00571	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—CCL20—psoriasis	0.000386	0.00567	CbGpPWpGaD
L-DOPA—Hyperhidrosis—Prednisone—psoriasis	0.000385	0.000428	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—psoriasis	0.000385	0.000428	CcSEcCtD
L-DOPA—Asthenia—Hydrocortisone—psoriasis	0.000384	0.000427	CcSEcCtD
L-DOPA—Vomiting—Cyclosporine—psoriasis	0.000383	0.000426	CcSEcCtD
L-DOPA—Rash—Cyclosporine—psoriasis	0.00038	0.000422	CcSEcCtD
L-DOPA—Anorexia—Prednisone—psoriasis	0.00038	0.000422	CcSEcCtD
L-DOPA—Dermatitis—Cyclosporine—psoriasis	0.00038	0.000422	CcSEcCtD
L-DOPA—Pruritus—Hydrocortisone—psoriasis	0.000379	0.000421	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—psoriasis	0.000379	0.000421	CcSEcCtD
L-DOPA—Headache—Cyclosporine—psoriasis	0.000378	0.00042	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—psoriasis	0.000377	0.000419	CcSEcCtD
L-DOPA—Feeling abnormal—Dexamethasone—psoriasis	0.000377	0.000419	CcSEcCtD
L-DOPA—Feeling abnormal—Betamethasone—psoriasis	0.000377	0.000419	CcSEcCtD
L-DOPA—Gastrointestinal pain—Dexamethasone—psoriasis	0.000374	0.000416	CcSEcCtD
L-DOPA—Gastrointestinal pain—Betamethasone—psoriasis	0.000374	0.000416	CcSEcCtD
L-DOPA—Vomiting—Mycophenolate mofetil—psoriasis	0.000374	0.000416	CcSEcCtD
L-DOPA—Hypersensitivity—Triamcinolone—psoriasis	0.000372	0.000413	CcSEcCtD
L-DOPA—Rash—Mycophenolate mofetil—psoriasis	0.000371	0.000412	CcSEcCtD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—CARM1—psoriasis	0.000371	0.00545	CbGpPWpGaD
L-DOPA—Dermatitis—Mycophenolate mofetil—psoriasis	0.00037	0.000412	CcSEcCtD
L-DOPA—Headache—Mycophenolate mofetil—psoriasis	0.000368	0.00041	CcSEcCtD
L-DOPA—Malaise—Methotrexate—psoriasis	0.000368	0.000409	CcSEcCtD
L-DOPA—Diarrhoea—Hydrocortisone—psoriasis	0.000366	0.000407	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—psoriasis	0.000365	0.000406	CcSEcCtD
L-DOPA—Urticaria—Dexamethasone—psoriasis	0.000364	0.000404	CcSEcCtD
L-DOPA—Urticaria—Betamethasone—psoriasis	0.000364	0.000404	CcSEcCtD
L-DOPA—Dizziness—Prednisolone—psoriasis	0.000363	0.000403	CcSEcCtD
L-DOPA—Asthenia—Triamcinolone—psoriasis	0.000362	0.000402	CcSEcCtD
L-DOPA—Abdominal pain—Betamethasone—psoriasis	0.000362	0.000402	CcSEcCtD
L-DOPA—Abdominal pain—Dexamethasone—psoriasis	0.000362	0.000402	CcSEcCtD
L-DOPA—Insomnia—Prednisone—psoriasis	0.00036	0.000401	CcSEcCtD
L-DOPA—Nausea—Cyclosporine—psoriasis	0.000358	0.000398	CcSEcCtD
L-DOPA—Paraesthesia—Prednisone—psoriasis	0.000358	0.000398	CcSEcCtD
L-DOPA—Pruritus—Triamcinolone—psoriasis	0.000357	0.000397	CcSEcCtD
L-DOPA—Cough—Methotrexate—psoriasis	0.000356	0.000396	CcSEcCtD
L-DOPA—Dizziness—Hydrocortisone—psoriasis	0.000354	0.000394	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—psoriasis	0.000354	0.000393	CcSEcCtD
L-DOPA—Dyspepsia—Prednisone—psoriasis	0.000351	0.00039	CcSEcCtD
L-DOPA—Nausea—Mycophenolate mofetil—psoriasis	0.000349	0.000388	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—psoriasis	0.000347	0.000386	CcSEcCtD
L-DOPA—Decreased appetite—Prednisone—psoriasis	0.000346	0.000385	CcSEcCtD
L-DOPA—Rash—Prednisolone—psoriasis	0.000346	0.000384	CcSEcCtD
L-DOPA—Dermatitis—Prednisolone—psoriasis	0.000345	0.000384	CcSEcCtD
L-DOPA—DRD5—GPCR downstream signaling—HCAR2—psoriasis	0.000344	0.00506	CbGpPWpGaD
L-DOPA—Fatigue—Prednisone—psoriasis	0.000344	0.000382	CcSEcCtD
L-DOPA—Headache—Prednisolone—psoriasis	0.000344	0.000382	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—psoriasis	0.000343	0.000382	CcSEcCtD
L-DOPA—DRD3—G alpha (i) signalling events—CCL20—psoriasis	0.000343	0.00504	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000342	0.00502	CbGpPWpGaD
L-DOPA—Constipation—Prednisone—psoriasis	0.000341	0.000379	CcSEcCtD
L-DOPA—Vomiting—Hydrocortisone—psoriasis	0.000341	0.000379	CcSEcCtD
L-DOPA—Rash—Hydrocortisone—psoriasis	0.000338	0.000375	CcSEcCtD
L-DOPA—Dermatitis—Hydrocortisone—psoriasis	0.000337	0.000375	CcSEcCtD
L-DOPA—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000337	0.00496	CbGpPWpGaD
L-DOPA—Confusional state—Methotrexate—psoriasis	0.000336	0.000373	CcSEcCtD
L-DOPA—Headache—Hydrocortisone—psoriasis	0.000336	0.000373	CcSEcCtD
L-DOPA—Dizziness—Triamcinolone—psoriasis	0.000334	0.000371	CcSEcCtD
L-DOPA—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000331	0.00487	CbGpPWpGaD
L-DOPA—Feeling abnormal—Prednisone—psoriasis	0.000328	0.000365	CcSEcCtD
L-DOPA—Asthenia—Betamethasone—psoriasis	0.000328	0.000365	CcSEcCtD
L-DOPA—Asthenia—Dexamethasone—psoriasis	0.000328	0.000365	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—psoriasis	0.000326	0.000363	CcSEcCtD
L-DOPA—Gastrointestinal pain—Prednisone—psoriasis	0.000326	0.000362	CcSEcCtD
L-DOPA—Nausea—Prednisolone—psoriasis	0.000326	0.000362	CcSEcCtD
L-DOPA—Pruritus—Dexamethasone—psoriasis	0.000324	0.00036	CcSEcCtD
L-DOPA—Pruritus—Betamethasone—psoriasis	0.000324	0.00036	CcSEcCtD
L-DOPA—Hyperhidrosis—Methotrexate—psoriasis	0.000322	0.000358	CcSEcCtD
L-DOPA—Vomiting—Triamcinolone—psoriasis	0.000321	0.000357	CcSEcCtD
L-DOPA—Nausea—Hydrocortisone—psoriasis	0.000318	0.000354	CcSEcCtD
L-DOPA—Rash—Triamcinolone—psoriasis	0.000318	0.000354	CcSEcCtD
L-DOPA—Dermatitis—Triamcinolone—psoriasis	0.000318	0.000353	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—psoriasis	0.000317	0.000353	CcSEcCtD
L-DOPA—Urticaria—Prednisone—psoriasis	0.000317	0.000352	CcSEcCtD
L-DOPA—DRD5—GPCR ligand binding—CCL20—psoriasis	0.000317	0.00465	CbGpPWpGaD
L-DOPA—Headache—Triamcinolone—psoriasis	0.000316	0.000351	CcSEcCtD
L-DOPA—Abdominal pain—Prednisone—psoriasis	0.000315	0.00035	CcSEcCtD
L-DOPA—Diarrhoea—Dexamethasone—psoriasis	0.000313	0.000348	CcSEcCtD
L-DOPA—Diarrhoea—Betamethasone—psoriasis	0.000313	0.000348	CcSEcCtD
L-DOPA—DRD5—Signaling by GPCR—HCAR2—psoriasis	0.000313	0.0046	CbGpPWpGaD
L-DOPA—Hypotension—Methotrexate—psoriasis	0.000311	0.000346	CcSEcCtD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000307	0.00451	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—LEP—psoriasis	0.000306	0.0045	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—HCAR2—psoriasis	0.000306	0.00449	CbGpPWpGaD
L-DOPA—Dizziness—Dexamethasone—psoriasis	0.000303	0.000336	CcSEcCtD
L-DOPA—Dizziness—Betamethasone—psoriasis	0.000303	0.000336	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—psoriasis	0.000301	0.000335	CcSEcCtD
L-DOPA—Nausea—Triamcinolone—psoriasis	0.0003	0.000333	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—psoriasis	0.000299	0.000333	CcSEcCtD
L-DOPA—DDC—Metabolism—NDUFA5—psoriasis	0.000299	0.00439	CbGpPWpGaD
L-DOPA—Dyspnoea—Methotrexate—psoriasis	0.000297	0.00033	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—psoriasis	0.000296	0.000329	CcSEcCtD
L-DOPA—Hypersensitivity—Prednisone—psoriasis	0.000294	0.000326	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—psoriasis	0.000293	0.000326	CcSEcCtD
L-DOPA—Vomiting—Dexamethasone—psoriasis	0.000291	0.000323	CcSEcCtD
L-DOPA—Vomiting—Betamethasone—psoriasis	0.000291	0.000323	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—psoriasis	0.00029	0.000322	CcSEcCtD
L-DOPA—Rash—Dexamethasone—psoriasis	0.000289	0.000321	CcSEcCtD
L-DOPA—Rash—Betamethasone—psoriasis	0.000289	0.000321	CcSEcCtD
L-DOPA—Dermatitis—Dexamethasone—psoriasis	0.000288	0.000321	CcSEcCtD
L-DOPA—Dermatitis—Betamethasone—psoriasis	0.000288	0.000321	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—psoriasis	0.000288	0.00032	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—psoriasis	0.000287	0.000319	CcSEcCtD
L-DOPA—Headache—Dexamethasone—psoriasis	0.000287	0.000319	CcSEcCtD
L-DOPA—Headache—Betamethasone—psoriasis	0.000287	0.000319	CcSEcCtD
L-DOPA—Asthenia—Prednisone—psoriasis	0.000286	0.000318	CcSEcCtD
L-DOPA—DDC—Circadian rythm related genes—NOS2—psoriasis	0.000285	0.0042	CbGpPWpGaD
L-DOPA—Pain—Methotrexate—psoriasis	0.000285	0.000317	CcSEcCtD
L-DOPA—Pruritus—Prednisone—psoriasis	0.000282	0.000313	CcSEcCtD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000276	0.00406	CbGpPWpGaD
L-DOPA—Feeling abnormal—Methotrexate—psoriasis	0.000274	0.000305	CcSEcCtD
L-DOPA—Diarrhoea—Prednisone—psoriasis	0.000273	0.000303	CcSEcCtD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000272	0.004	CbGpPWpGaD
L-DOPA—Gastrointestinal pain—Methotrexate—psoriasis	0.000272	0.000303	CcSEcCtD
L-DOPA—Nausea—Betamethasone—psoriasis	0.000272	0.000302	CcSEcCtD
L-DOPA—Nausea—Dexamethasone—psoriasis	0.000272	0.000302	CcSEcCtD
L-DOPA—DDC—Circadian rythm related genes—PPARG—psoriasis	0.000267	0.00392	CbGpPWpGaD
L-DOPA—Urticaria—Methotrexate—psoriasis	0.000265	0.000294	CcSEcCtD
L-DOPA—Dizziness—Prednisone—psoriasis	0.000264	0.000293	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—psoriasis	0.000263	0.000293	CcSEcCtD
L-DOPA—DRD2—G alpha (i) signalling events—CCL20—psoriasis	0.000262	0.00385	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—CP—psoriasis	0.000258	0.00379	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CYP2S1—psoriasis	0.000254	0.00374	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—HCAR2—psoriasis	0.000254	0.00374	CbGpPWpGaD
L-DOPA—Vomiting—Prednisone—psoriasis	0.000253	0.000282	CcSEcCtD
L-DOPA—Rash—Prednisone—psoriasis	0.000251	0.000279	CcSEcCtD
L-DOPA—Dermatitis—Prednisone—psoriasis	0.000251	0.000279	CcSEcCtD
L-DOPA—Headache—Prednisone—psoriasis	0.00025	0.000278	CcSEcCtD
L-DOPA—DDC—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000249	0.00366	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—CARM1—psoriasis	0.000246	0.00362	CbGpPWpGaD
L-DOPA—Hypersensitivity—Methotrexate—psoriasis	0.000245	0.000273	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—psoriasis	0.000239	0.000266	CcSEcCtD
L-DOPA—Nausea—Prednisone—psoriasis	0.000237	0.000263	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—psoriasis	0.000236	0.000262	CcSEcCtD
L-DOPA—DRD4—GPCR ligand binding—CCL20—psoriasis	0.000234	0.00343	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—JUN—psoriasis	0.000232	0.00341	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HCAR2—psoriasis	0.000231	0.00339	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—HCAR2—psoriasis	0.000229	0.00336	CbGpPWpGaD
L-DOPA—Diarrhoea—Methotrexate—psoriasis	0.000228	0.000253	CcSEcCtD
L-DOPA—DRD3—GPCR downstream signaling—HCAR2—psoriasis	0.000226	0.00332	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000223	0.00328	CbGpPWpGaD
L-DOPA—Dizziness—Methotrexate—psoriasis	0.00022	0.000245	CcSEcCtD
L-DOPA—SLC7A8—Hemostasis—NOS2—psoriasis	0.000219	0.00321	CbGpPWpGaD
L-DOPA—Vomiting—Methotrexate—psoriasis	0.000212	0.000235	CcSEcCtD
L-DOPA—DRD1—GPCR ligand binding—CCL20—psoriasis	0.00021	0.00309	CbGpPWpGaD
L-DOPA—Rash—Methotrexate—psoriasis	0.00021	0.000233	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—psoriasis	0.00021	0.000233	CcSEcCtD
L-DOPA—Headache—Methotrexate—psoriasis	0.000209	0.000232	CcSEcCtD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000209	0.00306	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HCAR2—psoriasis	0.000208	0.00305	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CCL20—psoriasis	0.000207	0.00305	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HCAR2—psoriasis	0.000205	0.00301	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000202	0.00298	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—CP—psoriasis	0.000201	0.00295	CbGpPWpGaD
L-DOPA—Nausea—Methotrexate—psoriasis	0.000198	0.00022	CcSEcCtD
L-DOPA—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000197	0.0029	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000191	0.00281	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—NOS2—psoriasis	0.000191	0.0028	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—JUN—psoriasis	0.000189	0.00278	CbGpPWpGaD
L-DOPA—PSIP1—Disease—HLA-A—psoriasis	0.000186	0.00274	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HCAR2—psoriasis	0.000185	0.00271	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CCL20—psoriasis	0.000179	0.00263	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—LEP—psoriasis	0.000178	0.00261	CbGpPWpGaD
L-DOPA—PSIP1—Disease—APOE—psoriasis	0.000174	0.00256	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—TNF—psoriasis	0.000174	0.00255	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—HCAR2—psoriasis	0.000173	0.00254	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—NOS2—psoriasis	0.000166	0.00243	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CCL20—psoriasis	0.000162	0.00239	CbGpPWpGaD
L-DOPA—PSIP1—Disease—NOS2—psoriasis	0.000162	0.00238	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TAGAP—psoriasis	0.00016	0.00235	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—LEP—psoriasis	0.00016	0.00235	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CCL20—psoriasis	0.000159	0.00233	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—LEP—psoriasis	0.000158	0.00232	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HCAR2—psoriasis	0.000157	0.00231	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—PPARG—psoriasis	0.000155	0.00227	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—NOS2—psoriasis	0.000149	0.00219	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—NOS2—psoriasis	0.000147	0.00216	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—IL6—psoriasis	0.00014	0.00206	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—PPARG—psoriasis	0.000139	0.00205	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—PPARG—psoriasis	0.000137	0.00202	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HCAR2—psoriasis	0.000136	0.002	CbGpPWpGaD
L-DOPA—PSIP1—Disease—TYK2—psoriasis	0.000133	0.00195	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CCL20—psoriasis	0.000132	0.00194	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—VEGFA—psoriasis	0.000127	0.00186	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—TP53—psoriasis	0.000125	0.00184	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CARM1—psoriasis	0.000124	0.00182	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HCAR2—psoriasis	0.000123	0.0018	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HCAR2—psoriasis	0.000121	0.00178	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—LEP—psoriasis	0.000121	0.00177	CbGpPWpGaD
L-DOPA—PSIP1—Disease—CD4—psoriasis	0.00012	0.00177	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCL20—psoriasis	0.00012	0.00176	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CCL20—psoriasis	0.000119	0.00175	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TAGAP—psoriasis	0.000118	0.00174	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CCL20—psoriasis	0.000117	0.00172	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—IL6—psoriasis	0.000114	0.00168	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—NOS2—psoriasis	0.000113	0.00165	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000112	0.00165	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—VEGFA—psoriasis	0.00011	0.00162	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—JUN—psoriasis	0.00011	0.00161	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCL20—psoriasis	0.000108	0.00159	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCL20—psoriasis	0.000106	0.00156	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TAGAP—psoriasis	0.000106	0.00156	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—PPARG—psoriasis	0.000105	0.00155	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TAGAP—psoriasis	0.000105	0.00154	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—CXCL8—psoriasis	0.000104	0.00153	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—JUN—psoriasis	9.88e-05	0.00145	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—JUN—psoriasis	9.75e-05	0.00143	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL20—psoriasis	9.6e-05	0.00141	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—TP53—psoriasis	9.56e-05	0.00141	CbGpPWpGaD
L-DOPA—PSIP1—Disease—STAT3—psoriasis	9.3e-05	0.00137	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HCAR2—psoriasis	9.27e-05	0.00136	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—CXCL8—psoriasis	9.25e-05	0.00136	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CCL20—psoriasis	8.97e-05	0.00132	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—CXCL8—psoriasis	8.55e-05	0.00126	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TP53—psoriasis	8.34e-05	0.00123	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	8.28e-05	0.00122	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL20—psoriasis	8.15e-05	0.0012	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TAGAP—psoriasis	8.03e-05	0.00118	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CAT—psoriasis	7.64e-05	0.00112	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—JUN—psoriasis	7.46e-05	0.0011	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	7.46e-05	0.0011	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	7.36e-05	0.00108	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—psoriasis	7.25e-05	0.00106	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL20—psoriasis	7.08e-05	0.00104	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—CXCL8—psoriasis	7.08e-05	0.00104	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NDUFA5—psoriasis	6.88e-05	0.00101	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—IL6—psoriasis	6.63e-05	0.000975	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—psoriasis	6.52e-05	0.000959	CbGpPWpGaD
L-DOPA—PSIP1—Disease—IL6—psoriasis	6.5e-05	0.000955	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—psoriasis	6.44e-05	0.000946	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL20—psoriasis	6.38e-05	0.000937	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CXCL8—psoriasis	6.31e-05	0.000927	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL20—psoriasis	6.29e-05	0.000924	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—IL6—psoriasis	5.97e-05	0.000877	CbGpPWpGaD
L-DOPA—DDC—Metabolism—APOE—psoriasis	5.93e-05	0.000872	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—IL6—psoriasis	5.89e-05	0.000866	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP2S1—psoriasis	5.85e-05	0.000859	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CXCL8—psoriasis	5.68e-05	0.000835	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.63e-05	0.000827	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CXCL8—psoriasis	5.6e-05	0.000823	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SOCS1—psoriasis	5.28e-05	0.000777	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PPARG—psoriasis	5.17e-05	0.00076	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—TYK2—psoriasis	5.04e-05	0.00074	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—psoriasis	4.92e-05	0.000724	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CXCL8—psoriasis	4.83e-05	0.00071	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL20—psoriasis	4.81e-05	0.000707	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—IL6—psoriasis	4.51e-05	0.000662	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CXCL8—psoriasis	4.39e-05	0.000645	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CXCL8—psoriasis	4.29e-05	0.00063	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SOCS1—psoriasis	3.9e-05	0.000573	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—LEP—psoriasis	3.9e-05	0.000573	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—APOE—psoriasis	3.9e-05	0.000573	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—TYK2—psoriasis	3.72e-05	0.000546	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NFKBIA—psoriasis	3.63e-05	0.000534	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCL8—psoriasis	3.56e-05	0.000524	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SOCS1—psoriasis	3.51e-05	0.000516	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SOCS1—psoriasis	3.46e-05	0.000509	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—TYK2—psoriasis	3.35e-05	0.000492	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—TYK2—psoriasis	3.3e-05	0.000485	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCL8—psoriasis	3.24e-05	0.000476	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCL8—psoriasis	3.21e-05	0.000472	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCL8—psoriasis	3.17e-05	0.000465	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TYK2—psoriasis	2.98e-05	0.000437	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL8—psoriasis	2.91e-05	0.000428	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APOE—psoriasis	2.88e-05	0.000423	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—LEP—psoriasis	2.88e-05	0.000423	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL8—psoriasis	2.88e-05	0.000423	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CARM1—psoriasis	2.86e-05	0.00042	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NFKBIA—psoriasis	2.68e-05	0.000394	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SOCS1—psoriasis	2.65e-05	0.00039	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL8—psoriasis	2.59e-05	0.000381	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOE—psoriasis	2.59e-05	0.000381	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—LEP—psoriasis	2.59e-05	0.000381	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—LEP—psoriasis	2.56e-05	0.000376	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOE—psoriasis	2.56e-05	0.000376	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—TYK2—psoriasis	2.53e-05	0.000371	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—psoriasis	2.46e-05	0.000362	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—psoriasis	2.42e-05	0.000356	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NFKBIA—psoriasis	2.41e-05	0.000355	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—JUN—psoriasis	2.41e-05	0.000354	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NFKBIA—psoriasis	2.38e-05	0.00035	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NFKB1—psoriasis	2.32e-05	0.000341	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—psoriasis	2.2e-05	0.000323	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TYK2—psoriasis	2.2e-05	0.000323	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—psoriasis	2.1e-05	0.000309	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—psoriasis	2.08e-05	0.000306	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TYK2—psoriasis	1.98e-05	0.000291	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LEP—psoriasis	1.96e-05	0.000287	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOE—psoriasis	1.96e-05	0.000287	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TYK2—psoriasis	1.95e-05	0.000287	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—psoriasis	1.91e-05	0.000281	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NFKBIA—psoriasis	1.82e-05	0.000268	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—psoriasis	1.82e-05	0.000267	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JUN—psoriasis	1.78e-05	0.000261	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAT—psoriasis	1.76e-05	0.000258	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—psoriasis	1.72e-05	0.000253	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NFKB1—psoriasis	1.71e-05	0.000252	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—psoriasis	1.7e-05	0.00025	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—psoriasis	1.64e-05	0.000241	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—psoriasis	1.62e-05	0.000237	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JUN—psoriasis	1.6e-05	0.000235	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—psoriasis	1.59e-05	0.000234	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JUN—psoriasis	1.58e-05	0.000232	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—psoriasis	1.55e-05	0.000228	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NFKB1—psoriasis	1.54e-05	0.000226	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—psoriasis	1.54e-05	0.000226	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NFKB1—psoriasis	1.52e-05	0.000223	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TYK2—psoriasis	1.49e-05	0.000219	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—psoriasis	1.46e-05	0.000214	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—psoriasis	1.4e-05	0.000205	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—psoriasis	1.38e-05	0.000203	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—psoriasis	1.38e-05	0.000203	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—psoriasis	1.37e-05	0.000201	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOE—psoriasis	1.36e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—psoriasis	1.3e-05	0.000191	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—psoriasis	1.24e-05	0.000182	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JUN—psoriasis	1.21e-05	0.000178	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARG—psoriasis	1.19e-05	0.000175	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—psoriasis	1.17e-05	0.000172	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NFKB1—psoriasis	1.16e-05	0.000171	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—psoriasis	1.07e-05	0.000158	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—psoriasis	1.06e-05	0.000155	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—psoriasis	1.06e-05	0.000155	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—psoriasis	1.05e-05	0.000154	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—psoriasis	1.04e-05	0.000153	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—psoriasis	9.67e-06	0.000142	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—psoriasis	9.54e-06	0.00014	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—psoriasis	7.98e-06	0.000117	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—psoriasis	7.3e-06	0.000107	CbGpPWpGaD
